Ozempic Not Working for Weight Loss? Here’s Why
Why doesn’t Ozempic work for me? The recent approval of semaglutide for weight loss has influenced many people to search for ways to be prescribed this wonderful weight loss drug.
- Ozempic is FDA-approved for type 2 diabetes, not weight loss. Wegovy is for weight loss.
- The maximum FDA-approved Ozempic dose is 2.0 mg weekly. The maximum FDA-approved Wegovy dose is now 7.2 mg weekly (as of March 2026).
- A 2025 study found patients treated by an obesity specialist were 8 times more likely to remain on GLP-1s.
- Rivas Medical Weight Loss has been treating obesity as a chronic disease for more than 34 years across 15 clinics in MD, VA, and FL.
You’re on Ozempic for weight loss, but there’s one major problem with that: This drug isn’t approved for weight loss.
That doesn’t mean it won’t work. But it does mean the dose ceiling is lower, the prescribing rules are different, and the conversation you should be having with your provider is probably not the one you’re having.
Let’s get specific.
Ozempic and Wegovy consist of the same molecule: Semaglutide. Same active ingredient, same mechanism, same family of side effects. However, they are not the same medication.
The FDA approved Ozempic in 2017 for type 2 diabetes with a maximum approved dose of 2.0 mg weekly. It’s labeled, marketed, and dosed for blood sugar control.
The FDA approved Wegovy in 2021 specifically for chronic weight management. Dose range now extends from 0.25 mg up to 7.2 mg weekly as of March 2026.
If you’ve been prescribed Ozempic to lose weight, you’re using it “off-label,” which is a common practice. The problem is that the maximum dose your prescriber can defensibly use is lower than what’s available with Wegovy. That alone can explain why the weight loss response feels weaker than what you saw on social media.
Practical takeaway: if weight loss is the goal, Wegovy or compounded semaglutide may be the appropriate treatment — not off-label Ozempic.
That’s a clinical conversation, not a Reddit thread. Find a prescriber who can have it with you.
Your Ozempic Dose May Be Capped Too Low
Ozempic’s FDA-approved dose range for diabetes goes up to 2.0 mg weekly. For most diabetes patients, that’s enough to manage blood sugar. For weight loss, it might not be. Wegovy’s approved range now reaches 7.2 mg. That is more than 3x the Ozempic ceiling.
If you’ve reached 2.0 mg of Ozempic and weight loss has stalled, you’ve hit the dose ceiling of that specific brand. The semaglutide molecule itself can do more at higher doses but not in an Ozempic formulation.
What to look for: A prescriber who understands the dosing limits of Ozempic for weight loss and is willing to transition you to Wegovy or another semaglutide formulation if clinically appropriate.
Learn more: Check out our GLP-1 Dose Calculator
You May Still Be in the Titration Phase
Ozempic, like Wegovy, starts at a sub-therapeutic dose of 0.25 mg weekly. That dose is for tolerability, not for blood sugar control or weight loss. Clinically meaningful response usually doesn’t appear until 1.0 mg or higher.
If you’ve been at 0.25 mg or 0.5 mg for more than two months and aren’t seeing results, that’s not the medication failing. That’s the medication doing what it’s meant to do at that dose: Get your body used to it.
What to look for: A prescriber who tracks your tolerance monthly and escalates the dose on a schedule built for your response, not on the manufacturer’s pre-set calendar.
Your Prescriber May Be Watching Your A1c, Not Your Weight
This is the clinical reality that catches the most patients off guard: Ozempic is a diabetes drug. If you were prescribed it by your primary care physician or endocrinologist, their clinical focus is your blood sugar, not weight. They may be cautious about escalating the dose if your A1c is already well controlled, even if your weight has plateaued.
The two goals require different treatment philosophies. One is built around hemoglobin A1c, kidney function, and cardiovascular risk markers. The other is built around body composition, appetite regulation, muscle preservation, and long-term behavioral support.
A diabetes prescriber will often optimize for the first set. An obesity medicine prescriber optimizes for the second.
What to look for: A prescriber whose primary clinical focus is obesity medicine, makes dose decisions around weight outcomes, body composition, and metabolic markers in addition to blood sugar.
The 8× Finding That Should Settle the Question
In a 2025 cross-sectional study published in Obesity Medicine, researchers tracked who was prescribing GLP-1 medications and how long their patients stuck with the treatment. Patients treated by an obesity specialist were 8 times more likely to remain on GLP-1 therapy than patients treated in general care settings.
The most common reasons patients stop GLP-1 therapy:
- Adverse effects: 52%
- Medication shortages: 33%
- Cost: 25%
An experienced obesity medicine practice can help you manage those common impediments by adjusting for side effects at each visit, working around shortages, and restructuring costs. The reason persistence is 8 times higher with an obesity specialist isn’t mysterious. It’s that the practice is structured for the actual cadence of GLP-1 care — weekly or monthly visits, a long-term relationship, real time to listen.
The Scale May Be Telling You a Misleading Story
Patients who feel like Ozempic isn’t working often are losing fat. They’re just not losing scale weight.
The scale measures everything: water, glycogen, food in transit, muscle, fat. Weekly fluctuations of two to four pounds in either direction are normal.
What to look for: A practice that tracks more than scale weight. Photos. Measurements. How clothes fit. The scale is one signal, not the only one.
Learn more about how to gauge your body composition changes and what else you can do to improve it
Lifestyle Is Quietly Doing Half the Work — or Half the Damage
Ozempic reduces appetite but it does not change what you eat when you do eat.
Patients who lose the most weight on GLP-1s tend to make protein-forward food choices, stay hydrated (GLP-1s slow gastric emptying and dehydrate patients faster than they realize), prioritize sleep, and add some form of strength training.
If you’re eating ultra-processed food in smaller quantities, dehydrated, and sleeping poorly, the medication is working as designed. The lifestyle is offsetting the results.
What to look for: A provider who actually talks to you about protein, water, sleep, and movement at every visit — not just dose.
Have you hit a Wegovy or Ozempic Plateau? Here’s what’s happening
Learn more: Check out our GLP-1 Protein and Water Calculator
How We Think About This at Rivas
We’ve been treating obesity as a chronic disease for more than 34 years.
When a patient walks in saying Ozempic isn’t working for them, the conversation almost always falls into one of three buckets:
- Stay on Ozempic, adjust the dose, lifestyle, or care cadence.
- Transition to Wegovy (the FDA-approved semaglutide for weight loss, with higher dose options) or to compounded semaglutide under provider supervision.
- Switch to a different molecule entirely — tirzepatide (Zepbound), which produced 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks in the SURMOUNT-5 trial.
The right answer depends on your medical history, what you’ve already tried, your goals, and your tolerance for side effects. It’s a conversation, not a decision made on a single visit.
What it isn’t: A primary care prescriber leaving you on the same Ozempic dose for a year and hoping the scale moves.
Considering a second opinion on your weight loss treatment?
Rivas has been a physician-led obesity medicine practice since 1991. Our providers prescribe Ozempic (when appropriate), Wegovy, compounded semaglutide, tirzepatide, and the full range of FDA-approved GLP-1s. The consultation is complimentary.
HSA & FSA accepted · Financing available
Related content:
- Weekly semaglutide dosing chart
- The Wegovy Pill: A Needle-Free GLP-1 Weight Loss Option
- Can you cut the Wegovy pill in half?
- Semaglutide Side Effects: Common vs. Serious
- Semaglutide: A Game-Changer in Weight Loss and Type 2 Diabetes Management
- Semaglutide Vs Phentermine
- Semaglutide vs. Liraglutide
- What does Semaglutide do to the body?
- How fast does semaglutide work?
FAQs
No. Ozempic is FDA-approved for type 2 diabetes management. Wegovy is the FDA-approved semaglutide medication for chronic weight management. They contain the same active ingredient but are dosed differently and labeled for different uses.
The most common reasons are reaching Ozempic’s 2.0 mg dose ceiling (which is lower than Wegovy’s), a prescriber focused on diabetes management rather than weight outcomes, an unrecognized plateau, or lifestyle factors offsetting the medication’s effect.
No. The 2.0 mg weekly dosage is the maximum FDA-approved Ozempic dose. If a higher semaglutide dose is clinically appropriate for weight loss, your provider may recommend Wegovy (approved up to 7.2 mg weekly) or compounded semaglutide.
If weight loss is your primary goal, Wegovy is FDA-approved for that indication and has higher dose options. Your provider can evaluate whether the switch is appropriate based on your history, response, and goals.
A 2025 study published in Obesity Medicine found that patients treated by an obesity specialist were 8 times more likely to persist on GLP-1 therapy than those treated in general care settings. The most common reasons patients discontinue (adverse effects, supply issues, cost) are challenges an experienced obesity medicine practice is built to navigate.
Compounded semaglutide is not the same as FDA-approved Wegovy. Compounded medications are prepared by licensed pharmacies and are not FDA-approved finished drug products. At Rivas, compounded semaglutide may be prescribed when clinically appropriate, under provider supervision.
Citations
- Liu S, et al. Factors contributing to non-persistence of glucagon-like peptide-1 agonists: a cross-sectional study. Obesity Medicine. 2025.
- Aronne LJ, et al. Tirzepatide vs Semaglutide for Treatment of Obesity. NEJM. 2025 (SURMOUNT-5).
- Lieberman DE, Aslan DH, Heymsfield SB. The conundrum of exercise for weight management in the GLP-1 receptor agonist era. JAMA. 2026.
- FDA approval announcement for Wegovy 7.2 mg, March 2026.
